IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.
Genecis is an early-stage organic waste processing startup that uses biotechnology to convert waste into biodegradeable plastics and other high value materials. Genecis is headquartered in Scarborough, Canada.
Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.
Ultima Genomics, founded in 2016 and based in Newark, California, specializes in genome-scale sequencing technology aimed at providing analytical services to enterprises. The company employs an innovative approach using an open substrate that creates a large, low-cost reaction surface, allowing for billions of reads without the need for expensive flow cells or complex fluidics. By integrating specialized sequencing hardware with machine learning, Ultima Genomics ensures reproducible and accurate results, enabling clients to obtain genomic reports rapidly and efficiently. This technology not only enhances the scale of genomic information but also significantly reduces the costs associated with sequencing, thereby facilitating advancements in biology and improvements in human health.
Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health. The company delivers insights to moms and families to make pregnancy safe. It was founded in 2018 by Maneesh Jain and is headquartered in South San Francisco, California, United States.
Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.
IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.
Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one.
They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body.
Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.
Apton Biosystems, Inc., founded in 2012 and based in Pleasanton, California, operates within the biotechnology sector, focusing on innovative solutions for genetic analysis. The company has developed a high-throughput and low-cost sequencing platform that enhances the availability of genetic testing, facilitating biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems reimagines optical systems for sequencing and single-molecule protein detection, utilizing super-resolution technology to evaluate closely spaced molecules. This approach enables the healthcare sector to create well-defined nanostructures, addressing spatial challenges and advancing high-density sequencing and protein detection capabilities. Through these advancements, Apton Biosystems contributes to the fields of preventive health and precision medicine.
Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.
Genalyte, Inc. is a clinical and diagnostic life science company based in San Diego, California, specializing in rapid diagnostic testing solutions. Founded in 2007, Genalyte has developed an innovative technology platform that utilizes silicon photonic biosensors to quantify biomolecular interactions, such as those between antibodies and proteins. This platform, known as the Maverick, allows for the direct measurement of protein binding and nucleic acid hybridization. Genalyte's technology is employed by healthcare providers, pharmaceutical companies, and academic researchers to monitor autoimmune diseases, screen for cancer biomarkers, detect anti-drug antibodies, and test for infectious agents, including Ebola. The company aims to enhance patient care by enabling rapid diagnostics, with tests typically completed in under thirty minutes, and providing mobile laboratory solutions for real-time diagnostics.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
Gen1E Lifesciences is a developer of a platform designed to accelerate cures for inflammatory and age-related diseases.The company's services include a pipeline of preclinical stage products that includes a P38 kinase inhibitor for the treatment of various inflammatory diseases, enabling medical researchers to optimize existing regulatory incentives, reduce the required R&D time and cost, truncate the time to exit and improve the success rate in receiving FDA approval and commercial success.
Probably Genetic is dedicated to assisting individuals with rare genetic conditions that are often misdiagnosed as autism spectrum disorder. Typically, patients endure an exhausting wait of up to seven years to receive accurate diagnoses, leading to significant emotional and financial burdens as they consult numerous doctors and specialists. To address this issue, Probably Genetic provides educational resources and DNA sequencing tests, facilitating a more straightforward path to understanding whether there may be underlying genetic factors contributing to their symptoms. The organization's goal is to support those who are overlooked by the existing healthcare system, ultimately helping families find clarity and answers more efficiently.
Loop Genomics is a platform technology for long-read DNA sequencing. Loop Genomics technology transforms short-read DNA sequencers into high-throughput, long-read, single-molecule DNA sequencing machines. Loop Genomics long-read DNA sequencing technology provides phased sequencing solutions across a diverse repertoire of research and clinical applications. Sequencing of partial rRNA gene sequences results in reduced phylogenetic resolution. Full-length, high-throughput, phased sequencing that covers all 16S variable regions is becoming the gold standard for profiling the microbiome. Achieve the highest resolution microbial community profiling with long-read, next-generation sequencing of the microbiome. Characterizing polymorphisms in HLA genes inside and outside of the protein-coding regions is important for organ transplantation compatibility testing and for strengthening causality association studies. The length of homologous sequences between HLA alleles extends beyond the capabilities of short-read sequencing platforms, resulting in diploid ambiguities and a reliance on imputation. Sequence full-length HLA DNA and/or RNA with phased, high throughput, long-read sequencing that resolves allelic discrimination and diploid ambiguity. Viral genetic variability is a major determinant of viral drug resistance and viral vaccine efficacy. Accurately mapping viral genetic variability is a critical step in choosing the optimal course of therapy and developing efficacious vaccines. Key mutations are typically located throughout long stretches of viral genomes, making the retrieval of critical phased data challenging using short-read sequencing technology. Use phased, high-throughput DNA sequencing technology to map key mutations at the quasi-species level and generate a complete phased map of viral populations.
Nebula Genomics, founded in 2016 and based in San Francisco, California, is a company focused on human genome sequencing and health data. It aims to create a comprehensive and trusted marketplace for genomic and health data, facilitating access for consumers, researchers, and the medical community. Utilizing blockchain technology, Nebula Genomics empowers individuals to control their genomic data while receiving compensation for its use. The marketplace aggregates extensive genetic information, which researchers can analyze to enhance drug development and streamline clinical trials, ultimately contributing to personalized medicine. The company's innovative DNA sequencing technology allows for the examination of all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, enabling clients to explore genetic variants comprehensively. Nebula Genomics was co-founded by Harvard genomics pioneer George Church and has received backing from notable investors.
Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health. The company delivers insights to moms and families to make pregnancy safe. It was founded in 2018 by Maneesh Jain and is headquartered in South San Francisco, California, United States.
Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in developing Eligobiotics, a novel class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, Eligo Bioscience utilizes a combination of the CRISPR/Cas system and engineered phage capsids to create antibiotics aimed at treating diseases associated with the human microbiome and resistant pathogens. Their innovative approach allows for the precise eradication of virulent bacteria, addressing the growing challenge of antibiotic resistance. The potential applications of their technology extend beyond therapeutics to include areas such as cosmetics and biodefense, positioning Eligo Bioscience at the forefront of next-generation antimicrobial development.
Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
Genalyte, Inc. is a clinical and diagnostic life science company based in San Diego, California, specializing in rapid diagnostic testing solutions. Founded in 2007, Genalyte has developed an innovative technology platform that utilizes silicon photonic biosensors to quantify biomolecular interactions, such as those between antibodies and proteins. This platform, known as the Maverick, allows for the direct measurement of protein binding and nucleic acid hybridization. Genalyte's technology is employed by healthcare providers, pharmaceutical companies, and academic researchers to monitor autoimmune diseases, screen for cancer biomarkers, detect anti-drug antibodies, and test for infectious agents, including Ebola. The company aims to enhance patient care by enabling rapid diagnostics, with tests typically completed in under thirty minutes, and providing mobile laboratory solutions for real-time diagnostics.
Color is a population health technology company founded in 2014 and based in Burlingame, California. It focuses on providing technology and infrastructure for large-scale health initiatives, making advanced healthcare services accessible and cost-effective. Color's Population Genomics Platform offers modular and comprehensive solutions designed to help health systems, employers, and research institutions develop and implement effective population health programs. The company combines innovative technology with specialized laboratory infrastructure and clinical services, facilitating various aspects of health programs, including strategy, participant engagement, genetic testing, data management, and clinical reporting. Color’s partnerships with organizations such as the National Institutes of Health and Verily enhance its capabilities, enabling it to deliver precision health programs that address the challenges of traditional healthcare access and costs.
Genalyte, Inc. is a clinical and diagnostic life science company based in San Diego, California, specializing in rapid diagnostic testing solutions. Founded in 2007, Genalyte has developed an innovative technology platform that utilizes silicon photonic biosensors to quantify biomolecular interactions, such as those between antibodies and proteins. This platform, known as the Maverick, allows for the direct measurement of protein binding and nucleic acid hybridization. Genalyte's technology is employed by healthcare providers, pharmaceutical companies, and academic researchers to monitor autoimmune diseases, screen for cancer biomarkers, detect anti-drug antibodies, and test for infectious agents, including Ebola. The company aims to enhance patient care by enabling rapid diagnostics, with tests typically completed in under thirty minutes, and providing mobile laboratory solutions for real-time diagnostics.
Genalyte, Inc. is a clinical and diagnostic life science company based in San Diego, California, specializing in rapid diagnostic testing solutions. Founded in 2007, Genalyte has developed an innovative technology platform that utilizes silicon photonic biosensors to quantify biomolecular interactions, such as those between antibodies and proteins. This platform, known as the Maverick, allows for the direct measurement of protein binding and nucleic acid hybridization. Genalyte's technology is employed by healthcare providers, pharmaceutical companies, and academic researchers to monitor autoimmune diseases, screen for cancer biomarkers, detect anti-drug antibodies, and test for infectious agents, including Ebola. The company aims to enhance patient care by enabling rapid diagnostics, with tests typically completed in under thirty minutes, and providing mobile laboratory solutions for real-time diagnostics.
Editas Medicine is a clinical-stage company focused on developing innovative genome editing therapeutics to address serious diseases at the genetic level. Established in 2013 and headquartered in Cambridge, Massachusetts, with an additional site in Boulder, Colorado, the company leverages its proprietary CRISPR/Cas9 technology to create precise and corrective molecular modifications. This approach utilizes a protein-RNA complex, which includes the Cas9 enzyme and a guide RNA, to target and repair specific DNA sequences. Editas Medicine aims to translate its advances in genome editing into transformative human therapies, supported by a robust portfolio of patents and intellectual property that underpins its foundational technologies.
Color is a population health technology company founded in 2014 and based in Burlingame, California. It focuses on providing technology and infrastructure for large-scale health initiatives, making advanced healthcare services accessible and cost-effective. Color's Population Genomics Platform offers modular and comprehensive solutions designed to help health systems, employers, and research institutions develop and implement effective population health programs. The company combines innovative technology with specialized laboratory infrastructure and clinical services, facilitating various aspects of health programs, including strategy, participant engagement, genetic testing, data management, and clinical reporting. Color’s partnerships with organizations such as the National Institutes of Health and Verily enhance its capabilities, enabling it to deliver precision health programs that address the challenges of traditional healthcare access and costs.
Apton Biosystems, Inc., founded in 2012 and based in Pleasanton, California, operates within the biotechnology sector, focusing on innovative solutions for genetic analysis. The company has developed a high-throughput and low-cost sequencing platform that enhances the availability of genetic testing, facilitating biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems reimagines optical systems for sequencing and single-molecule protein detection, utilizing super-resolution technology to evaluate closely spaced molecules. This approach enables the healthcare sector to create well-defined nanostructures, addressing spatial challenges and advancing high-density sequencing and protein detection capabilities. Through these advancements, Apton Biosystems contributes to the fields of preventive health and precision medicine.
Codon Devices
Series B in 2006
Codon Devices is a biotechnology company, engages in developing, constructing, and delivering synthetic biology products for research. The company focuses on discovering and manufacturing synthetic biological parts. Its BioLOGIC Engineering Platform combines sophisticated design algorithms with assay and protein engineering capabilities to result in a system for the design, discovery, and optimization of proteins for specific applications; and BioFAB Production Platform, which produces synthetic genes.